Ontario Teachers' Pension Plan Board v. Teva Pharmaceutical Industries Ltd.

District Court, D. Connecticut·Decided March 30, 2021·No. 3:17-cv-00558·Unknown

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF CONNECTICUT

___________________________________

IN RE TEVA SECURITIES LITIGATION No. 3:17-cv-558 (SRU) ___________________________________

THIS DOCUMENT RELATES TO: No. 3:19-cv-513 (SRU) ___________________________________ No. 3:19-cv-655 (SRU) No. 3:19-cv-657 (SRU) No. 3:19-cv-923 (SRU) No. 3:19-cv-1167 (SRU) No. 3:20-cv-83 (SRU)

RULING AND ORDER

In this consolidated action,1 numerous plaintiffs have sued Teva Pharmaceutical Industries, Ltd. (“Teva”), and several of Teva’s current and former employees and officers (the “Defendants”). In the main, the plaintiffs allege that the Defendants violated federal securities laws by misrepresenting the reasons for Teva’s financial success. More specifically, the plaintiffs allege that the Defendants publicly attributed Teva’s success to good business decisions when, in fact, Teva was thriving because it was artificially and collusively inflating the prices of certain generic drugs that it manufactured. This ruling addresses a motion for reconsideration or, in the alternative, for interlocutory appeal made by opt-out plaintiffs in six direct actions (the “Reconsideration Plaintiffs”).2

1 I have consolidated the over two-dozen cases pending before me related to the same subject matter. See Consolidation Ruling, Doc. No. 341 (also available at Ontario Teachers’ Pension Plan Bd. v. Teva Pharm. Indus., Ltd., 2020 WL 1181366 (D. Conn. Mar. 10, 2020)); Consolidation Order, Doc. No. 352. The consolidated case consists of four class actions that are consolidated for all purposes and twenty-one “direct” actions consolidated for all pre-trial purposes in which the plaintiffs have indicated that they will “opt out” of the class that I have now certified. See In re Teva Sec. Litig., 2021 WL 872156 (D. Conn. Mar. 9, 2021). 2 Those are: (1) Mivtachim The Workers Social Ins. Fund, Ltd., et al. v. Teva Pharm. Indus., Ltd., et al., No. 3:19-cv-513; (2) Migdal Ins. Co., Ltd., et al. v. Teva Pharm. Indus., Ltd., et al., No. 3:19-cv-655; (3) Oregon v. Teva Pharm. Indus., Ltd., et al., No. 3:19-cv-657; (4) Migdal Mut. Funds, Ltd. v. Teva Pharm. Indus., Ltd., et al., No. 3:19-cv-923; (5) Psagot Mut. Funds, Ltd., et al. v. Teva Pharm. Indus., Ltd., et al., No. 3:19-cv-1167; and (6) Internationale Kapitalanlagegesellschaft mbH v. Teva Pharm. Indus., Ltd., et al. (“INKA”), No. 3:20-cv-83. Recently, I granted the Defendants’ partial motion to dismiss portions of the Reconsideration Plaintiffs’ claims that were barred by relevant statutes of repose. See In re Teva Sec. Litig., 2021 WL 231130, at *3–12 (D. Conn. Jan. 22, 2021) (the “Repose Ruling”). The Reconsideration Plaintiffs ask me to reconsider my Repose Ruling or, in the alternative, to certify it for

interlocutory appeal. For the following reasons, the Reconsideration Plaintiffs’ motion is denied. I. My Repose Ruling and Procedural Background

The Reconsideration Plaintiffs bring claims, in relevant part, pursuant to Section 10(b) of the Securities Exchange Act of 1934, 15 U.S.C. § 78j(b) (the “Exchange Act”), and Rule 10b-5 promulgated thereunder, 17 C.F.R. § 240.10b-5, and the analogous provisions of the Pennsylvania Securities Act of 1972 (the “PSA”). The Exchange Act contains a five-year statute of repose applicable to claims brought pursuant to Section 10(b) and Rule 10b-5. See 28 U.S.C. § 1658(b)(2) (explaining, in relevant part, that a Section 10(b) or Rule 10b-5 claim “may be brought not later than . . . 5 years after such violation”). The PSA contains an analogous time- bar. See 70 Pa. Stat. § 1-504(a). On January 22, 2021, I granted the Defendants’ partial motion to dismiss the Reconsideration Plaintiffs’ Section 10(b), Rule 10b-5, and PSA claims to the extent that they were based on misstatements or omissions that occurred more than five years before the Reconsideration Plaintiffs filed their complaints. See Repose Ruling, 2021 WL 231130, at *12. I explained that the crucial question was whether the “Repose Clock” started “running from the

Curiously, the plaintiffs in three other direct actions that were affected by my Repose Ruling did not join the Reconsideration Plaintiffs in the instant motion. The Reconsideration Plaintiffs do not explain the omission. Those three actions are: (1) Schwab Capital Tr., et al. v. Teva Pharm. Indus., Ltd., et al., No. 3:19-cv-192; (2) Stichting PGGM Depositary, et al. v. Teva Pharm. Indus., Ltd., et al., No. 3:19-cv-1173; and (3) Boeing Co. Emp. Ret. Plans Master Tr. v. Teva Pharm. Indus., Ltd., et al., No. 3:20-cv-588. date of each alleged misstatement or omission,” or, rather, “only from the date of the last alleged misstatement or omission that could give rise [to] liability under the Exchange Act.” Id. at *4. (I will refer to that issue as the “Repose Clock issue.”) I held that the Repose Clock in Section 1658(b) begins running at the date of each alleged misstatement or omission because each such

allegation could establish a “violation” of Section 10(b). See id. at *8. In doing so, I acknowledged that the Repose Clock issue was “a relatively open issue” that was “not cut-and- dried.” Id. at *5. Although both sides “cite[d] numerous district court cases supporting their respective interpretations,” I held that the “Defendants’ citations are stronger” because “they are more recent, and they include cases in which district courts within the Second Circuit have granted the precise relief that the Repose Defendants seek here.” Id. at *7 & nn.15–16. In the interest of completeness, I then addressed an argument that the Reconsideration Plaintiffs had not briefed. I explained: At the hearing on this pending motion to dismiss, the [Reconsideration] Plaintiffs seemed to gesture at a new theory for liability. The [Reconsideration] Plaintiffs mentioned that the [] Defendants were involved in a years-long fraudulent “scheme” and that Rule 10b-5 “allows [for] scheme liability.”

Id. at *8 (citing Hr’g Tr., Doc. No. 647, at 23:3–25:12). I then explained why the Defendants had not alleged a claim for scheme liability. First, I noted distinctions between misstatement and omissions cases and scheme liability cases. For instance, citing recent caselaw from the Southern District of New York and the Central District of California, I noted that Rule 10b-5’s three subsections3 were distinct in

3 Rule 10b-5 has three subsections and reads as follows:

It shall be unlawful for any person, directly or indirectly, by the use of any means or instrumentality of interstate commerce, or of the mails or of any national securities exchange,

(a) To employ any device, scheme, or artifice to defraud, important ways: “Rule 10b-5(b) applies to misrepresentation or omission claims, and Rules 10b- 5(a) and (c) apply to scheme liability claims.” Id. (quoting Fischler Kapel Holdings, LLC v. Flavor Producers, LLC, 2020 WL 6939887, at *8 (C.D. Cal. Nov. 25, 2020)). I remarked that “[w]here the primary purpose and effect of a purported scheme is to make a public

misrepresentation or omission, courts have routinely rejected the plaintiff’s attempt to bypass the elements necessary to impose misstatement liability under subsection (b) by labeling the alleged misconduct a scheme rather than a misstatement.” Id. at *9 (quoting In re Mindbody, Inc. Sec. Litig., 2020 WL 5751173, at *19 (S.D.N.Y. Sept. 25, 2020)). I held that the Reconsideration Plaintiffs had not alleged a “scheme liability” claim for “several reasons,” both formal and substantive. Id. First, I remarked that “these cases are plainly misstatements and omissions cases.” Id.

Free access — add to your briefcase to read the full text and ask questions with AI

Ontario Teachers' Pension Plan Board v. Teva Pharmaceutical Industries Ltd., (D. Conn. 2021).

Ontario Teachers' Pension Plan Board v. Teva Pharmaceutical Industries Ltd. (Ontario Teachers' Pension Plan Board v. Teva Pharmaceutical Industries Ltd.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

In re The City of New York
607 F.3d 923 (Second Circuit, 2010)
Bruce C. Shrader v. Csx Transportation, Inc.
70 F.3d 255 (Second Circuit, 1995)
Analytical Surveys, Inc. v. Tonga Partners, L.P.
684 F.3d 36 (Second Circuit, 2012)
Balintulo v. Daimler AG
727 F.3d 174 (Second Circuit, 2013)
Century Pacific, Inc. v. Hilton Hotels Corp.
574 F. Supp. 2d 369 (S.D. New York, 2008)
Williston v. Eggleston
410 F. Supp. 2d 274 (S.D. New York, 2006)
Consub Delaware LLC v. Schahin Engenharia Limitada
476 F. Supp. 2d 305 (S.D. New York, 2007)
Ryan, Beck & Co., LLC v. Fakih
275 F. Supp. 2d 393 (E.D. New York, 2003)
In Re World Trade Center Disaster Site Litigation
469 F. Supp. 2d 134 (S.D. New York, 2007)
Salim Oleochemicals, Inc. v. M/V SHROPSHIRE
177 F. Supp. 2d 159 (S.D. New York, 2001)
Mei Xing Yu v. Hasaki Restaurant, Inc.
874 F.3d 94 (Second Circuit, 2017)
Lorenzo v. SEC. & Exch. Comm'n
587 U.S. 71 (Supreme Court, 2019)
Sequa Corp. v. GBJ Corp.
156 F.3d 136 (Second Circuit, 1998)
Buehlman v. IDE Pontiac, Inc.
268 F. Supp. 3d 437 (W.D. New York, 2017)
Phillips ex rel. B.P. v. City of New York
775 F.3d 538 (Second Circuit, 2015)